An innovative oral management procedure to reduce postoperative complications

Akari Kaga, DH,a Tetsuya Ikeda, DDS, PhD,a Keisei Tachibana, MD, PhD,b Ryota Tanaka, MD, PhD,b Haruhiko Kondo, MD, PhD,b Takanori Kawabata, MS,c Tomoko Yorozu, MD, PhD,d and Koichiro Saito, MD, PhD,e

ABSTRACT

Background: Numerous studies have shown that improving oral hygiene contributes to a reduction in the risk of postoperative complications in patients with head and neck cancer, cardiac disease, and esophageal cancer. However, the beneficial standard for oral management procedures during the perioperative period has not yet been established. Therefore, our aim was to determine whether or not their innovative oral management intervention contributed to a reduction in postoperative complications in lung cancer.

Methods: We performed a retrospective analysis of medical records of patients who underwent lung cancer surgery with lobectomy and pneumonectomy at Kyorin University Hospital. Patients were divided into 2 groups: a perioperative oral management intervention group that underwent lung cancer surgery from April 2016 to March 2018 (n = 164), and a control group without oral management that underwent surgery from April 2014 to March 2016 (n = 199). In particular, our oral management procedure emphasized oral mucosa stimulation to induce saliva discharge as in gum chewing, rather than simply using teeth brushing to reduce oral microbiome. Therefore, our oral management procedure is different from traditional oral care.

Results: This study demonstrated that our oral management practice was associated with a decline in the occurrence of postoperative pneumonia (odds ratio, 0.184; 95% CI, 0.042-0.571; P = .009), postoperative hospital stay duration (β coefficient, −4.272; 95% CI, −6.390 to −2.155; P < .001) and Clavian-Dindo classification grade II or above (odds ratio, 0.503; 95% CI, 0.298-0.835; P = .009).

Conclusions: We propose an innovative new strategy using their unique oral management procedure to reduce postoperative complications resulting from pulmonary resection. (JTCVS Open 2022;10:442-53)

CENTRAL MESSAGE
Our innovative oral management procedure is safe, efficient, cost-effective, and cogent; it could be applied in hospitals immediately.

Perspective
This study reveals that, in cases of pulmonary resection, our innovative oral management procedure has a propensity to decrease the development of postoperative pneumonia and Clavien-Dindo classification II or above when compared to the nonintervention group. Furthermore, our intervention leads to a decrease in postoperative hospital stay compared to the nonintervention group.

See Commentary on page 454.

Postoperative complications are associated with increased mortality, postoperative hospital stay, and cost.1-3 Numerous studies show that improving oral hygiene contributes to a reduction in the risk of postoperative complications in patients with cardiac disease1 and lung cancer.4 Furthermore, postoperative pneumonia in esophageal cancer patients was reduced from 32% to 9% by brushing their teeth 5 times a day commencing 1 week before the date of the operation.5 A study of patients undergoing cardiac surgery revealed those with unsatisfactory oral hygiene had 12 times the chance of developing postoperative pneumonia.
Postoperative pneumonia is still a common complication after lung resection, affecting 41 of 441 patients (9.3%). Iwata and colleagues reported that patients who received perioperative oral care from a dentist and a dental hygienist experienced fewer complications after lung resection, 13 of 280 patients (4.6%), than patients who received no perioperative oral care, 41 of 441 patients (9.3%). In addition, Postoperative pneumonia is still a common complication after major pulmonary resections, with an incidence of 5.0% to 10.9%. Therefore, reducing the frequency of postoperative pneumonia remains a problem.

Ishimaru and colleagues described that in patients with esophageal, gastric, and colon cancers there is a significant statistical relationship between oral care and postoperative complications. In contrast, there is no statistically significant relationship between oral care and postoperative pneumonia in patients with lung, liver, and head-neck cancers. Therefore, the relationship between preoperative oral care and postoperative complications may be greater in patients with gastrointestinal tract cancer than in patients with other types of cancer (eg, liver, lung, and head-neck cancer). Thus, these reports indicate that the beneficial standard for oral care during the perioperative period has not yet been established.

Researchers estimate that the oral microbiome includes more than 500 bacterial species. Poor oral hygiene was among the risk factors contributing to nosocomial infection. Also, many microorganisms of tracheal aspirate cultures were concordant with dental plaque bacteria. Researchers recognized that the endotracheal tube served as a vehicle for provider microorganisms to the lower respiratory tract. Judging from those reports, improving oral hygiene before the operation would have significant benefits in patients who also had a surgical wound site on the lung.

Since 2015, Kyorin University Hospital anesthesiologists have examined all patients scheduled to undergo surgery under general anesthesia, before their surgery. In the same department, since April 2016, Kyorin University Hospital dental staff members have checked the oral condition of all patients who underwent surgery under general anesthesia, including primary malignant pulmonary tumor resection. The purpose of this study is to determine whether or not our new oral management intervention, mainly characterized by oral mucosa stimulation with a toothbrush, contributes to a reduction in postoperative complications, hospital stay period, and postoperative complications resulting from pulmonary resection.

**METHODS**

**Patients**

We performed a retrospective analysis of medical records of patients who underwent lung cancer surgery from April 2014 to March 2018 at Kyorin University Hospital. We extracted those patients who underwent lobectomy and pneumonectomy, leaving 363 patients in this study; 357 patients underwent lobectomy and 6 patients underwent pneumonectomy. The exclusion criteria were operative procedures on the other lung surgery, including wedge resection and segmentectomy, emergency surgery, palliative surgery, noncancer disease, and metastasis. We excluded 31 patients comprising 10 who rejected or received an incomplete oral intervention procedure, 2 with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or greater, 11 with multifocal lung cancer, 4 with unknown histologic type, 2 with latent carcinoma, and 2 patients with a certain postoperative complication history.

We divided the study’s patients into 2 groups: an oral management intervention group that underwent lung cancer surgery from April 2016 to March 2018 and was assessed by a dentist and a dental hygienist during the perioperative period (n = 164), and a control group, without oral management, that underwent lung cancer surgery from April 2014 to March 2016 (n = 199) (Figure 1). Our intervention period extended from 2 weeks before surgery to the time when patients could intake orally and discharge adequate salivary flow.

**Complication Diagnosis**

We diagnosed pneumonia in accordance with reports from previous researchers. Furthermore, we defined and assessed postoperative complication according to Clavien-Dindo (C-D) classification.

**Oral Management**

Before admission, we conducted common oral hygiene practice and instruction, such as dental scaling, removal of plaque with a toothbrush, cleaning of dentures, and use of an oral rinse, excluding a disinfectant agent. It also included dental extraction where there was severe periodontitis showing pain, pus discharge, and mobility before the operation. The purpose of this tooth extraction was to facilitate smooth intubation. As a result, 9 patients had a total of 12 teeth extracted. We emphasized that our instructions were to improve oral hygiene but more importantly for patients to stimulate oral mucosa by themselves with a toothbrush, as many times as possible (See Figures 2 and 3). This oral mucosa stimulation process is the foundation of our oral management procedure, and is clearly shown in the accompanying Video 1. We instructed patients to continue this procedure from the day of assessment of their oral condition at the perioperative management center, through the surgery period and afterward, until their general condition improved. Specifically, the time immediately before going to the operating theatre is especially important for this oral stimulation. This is because we believe oral mucosa stimulation acts as sham feeding that may induce bowel movement as in gum chewing.

Because our oral stimulation with a toothbrush moved jaw muscles, this procedure may have induced saliva secretion. In contrast, we did not use some oral management practices widely accepted among health professionals. These included measurement of periodontal pocket depth, the use of oral rinse, including an oral antiseptic agent (eg, chlorhexidine gluconate), and cleaning of the tongue surface. Also, decayed teeth were sealed with filling materials. Therefore, our oral management procedure of oral mucosa stimulation with a toothbrush begins during the preoperative period and continues right through until there is an improvement in general condition after surgery (See Figure 3).

**Variables**

We examined the following variables using the patients’ medical records: age, gender, body mass index, ECOG PS, vital capacity, forced expiratory volume for 1 second expressed as a percentage of the forced vital
capacity, comorbidities (eg, artificial dialysis, interstitial pneumonia, ischemic cardiac disease, cranial nerve disease or cerebrovascular disorder, diabetes mellitus, autoimmune disorder, arrhythmia, and hypertension), smoking status, preoperative therapy, size of tumor, surgical side, albumin, operation time, blood loss, surgical approach, histologic type, pathologic staging, and postoperative outcomes, such as postoperative hospital stay duration, postoperative pneumonia, and C-D classification. In this study, we regarded patients with postoperative complications as having C-D classification grade II or above.

**Statistical Analysis**

We assessed categorical variables with Fisher exact test and continuous variables using the Mann-Whitney U test. We performed negative binomial...
regression analysis to evaluate the association with postoperative hospital stay duration. We conducted logistic regression analysis for binary data such as the occurrence of postoperative pneumonia and C-D classification II or greater. We included variables with \( P < .05 \) on univariate analysis in the subsequent multivariate regression analysis and we applied this criterion for both negative binomial and logistics regression analysis. We performed all statistical analyses using R version 3.6.1 (R Foundation for Statistical Computing).

**RESULTS**

The study analyzed the background data of 363 patients in 2 groups. The oral management group comprised 164 patients with 114 (69.5\%) men and 50 (30.5\%) women with...
an average age of 69 years (range, 30-91 years). The control group comprised 199 patients with 123 (61.8\%\) men and 76 (38.2\%) women with an average age of 69 years (range, 38-90 years). In addition, Tables 1 and 2 show that gender, age, body mass index, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity, comorbidities (eg, artificial dialysis, interstitial pneumonia, ischemic cardiac disease, cranial nerve disease or cerebrovascular disorder, diabetes mellitus, autoimmune disorder, and arrhythmia), smoking status, preoperative therapy, surgery side, surgical approach, and histologic type were evaluated and there were no significant differences between the 2 groups. In contrast, PS, vital capacity, hypertension, size of tumor, and albumin level were detected differences.

Table 2 shows patients who underwent oral management had an average postoperative hospital stay of 8 days (range, 2-113 days) compared with 9 days for patients without oral management (range, 4-89 days; \(P = .029\)). There was also a significant difference in the occurrence of postoperative pneumonia between the oral management group, 3 of 164 patients (1.8\%) and the control group, 19 of 199 patients (9.6\%) (\(P = .002\)). This significant difference was also reflected in patients with a C-D classification of grade II or greater, 31 of 164 patients (18.9\%) in the care group and 59 of 199 patients (29.6\%) (\(P = .02\)) in the control group.

Table 3 shows that oral management (odds ratio [OR], 0.184; 95\% CI, 0.042-0.571; \(P = .009\)) was the only relative factor for postoperative pneumonia.

Table 4 describes the associations between patient characteristics and the length of postoperative hospital stay. The negative binomial regression analysis found 5 predictor factors that were also associated with the length of postoperative hospital stay in this study: oral management (\(b\) coefficient, –4.272; 95\% CI, –6.390 to –2.155; \(P < .001\)), PS (\(b\) coefficient, 1.246; 95\% CI, 1.033-1.507; \(P = .022\)), size of tumor (\(b\) coefficient, 0.856; 95\% CI, 0.096-1.617; \(P = .027\)), operation time (\(b\) coefficient, 0.030; 95\% CI, 0.013-0.046; \(P < .001\)), blood loss (\(b\) coefficient, 0.004; 95\% CI, 0.000-0.008; \(P = .009\)).

| TABLE 1. Patient characteristics and surgical information |
|-----------------------------------------------|-----------------------------|-----------------------------|--|
| Characteristic                          | Oral management group (n = 164) | No oral management group (n = 199) | \(P\) value |
| Gender                                  |                             |                             |--|
| Male                                    | 114 (69.5)                  | 123 (61.8)                  | .150 |
| Female                                  | 50 (30.5)                   | 76 (38.2)                   | \--|
| Age (y)                                 | 69 (30-91)                  | 69 (38-90)                  | .768 |
| Body mass index                         | 22.75 (16.19-32.71)         | 22.75 (0.00-42.31)          | .663 |
| ECOG performance status                 |                             |                             |--|
| 0                                       | 155 (94.5)                  | 171 (85.9)                  | .008*|
| 1                                       | 9 (5.5)                     | 28 (14.1)                   | \--|
| %VC                                     | 103.40 (24.30-1306.00)      | 108.40 (42.50-153.50)       | .012*|
| %FEV1                                   | 73.30 (45.90-717.00)        | 74.20 (27.10-708.00)        | .202 |
| Comorbidities                           |                             |                             |--|
| Artificial dialysis                     | 1 (0.6)                     | 1 (0.5)                     | 1.000 |
| Interstitial pneumonia                  | 2 (1.2)                     | 3 (1.5)                     | 1.000 |
| Ischemic cardiac disease                | 4 (2.4)                     | 13 (6.7)                    | .080 |
| Cranial nerve disease or cerebrovascular disorder | 4 (2.4) | 11 (5.6) | .186 |
| Diabetes mellitus                       | 22 (13.4\%)                 | 29 (14.9)                   | .762 |
| Autoimmune disorder                     | 2 (1.2\%)                   | 1 (0.5)                     | .594 |
| Arrhythmia (medical treatment)          | 6 (3.7)                     | 6 (3.1)                     | .777 |
| Hypertension                            | 49 (29.9)                   | 9 (4.6)                     | <.001*|
| Smoking status                          |                             |                             |--|
| Never smoked                            | 42 (39.3)                   | 65 (60.7)                   | .301 |
| Quit \(\geq 30\) d before surgery/exsmoker | 103 (47.0)                  | 116 (53.0)                  | \--|
| Quit \(< 30\) d before surgery/still smoking | 19 (51.4)                  | 18 (48.6)                   | \--|
| Preoperative therapy                     | 1 (0.6)                     | 4 (2.0)                     | .383 |
| Size of tumor (cm)                       | 2.90 (0.90-9.20)            | 2.50 (0.80-9.10)            | .001*|
| Side                                    |                             |                             |--|
| Right                                   | 112 (68.3)                  | 132 (66.3)                  | .737 |
| Left                                    | 52 (31.7)                   | 67 (33.7)                   | \--|
| Albumin (g/dL)                          | 4.20 (2.60-5.00)            | 4.30 (2.50-5.20)            | .017*|

Values are presented as median (min-max) or n (%). ECOG, Eastern Cooperative Oncology Group; %VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity. *\(P < .05\).
TABLE 2. Clinical outcome and surgical related information

| Variable                        | Oral management group (n = 164) | No management group (n = 199) | P value |
|--------------------------------|---------------------------------|------------------------------|---------|
| Operation time (min)           | 238.5 (99.0-598.0)              | 209.0 (90.0-515.0)           | <.001*  |
| Blood loss (mL)                | 29.5 (0-6162)                   | 39 (2-811)                   | .032*   |
| Surgical approach              |                                 |                              |         |
| VATS                           | 156 (95.1)                      | 195 (98.0)                   | .149    |
| Thoracotomy                    | 8 (4.9)                         | 4 (2.0)                      |         |
| Histologic type                |                                 |                              |         |
| Adenocarcinoma                 | 112 (68.3)                      | 145 (72.9)                   | .355    |
| Nondencarcinoma                | 52 (31.7)                       | 54 (27.1)                    |         |
| Pathologic staging             |                                 |                              |         |
| 0                              | 4 (2.4)                         | 6 (3.0)                      | <.001*  |
| IA and IB                      | 70 (42.7)                       | 122 (61.3)                   |         |
| IIA and IIB                    | 40 (24.4)                       | 42 (21.1)                    |         |
| IIIA and IIB                   | 37 (22.6)                       | 28 (14.1)                    |         |
| IV                             | 13 (7.9)                        | 1 (0.5)                      |         |
| Clavien-Dindo classification   | 31 (18.9)                       | 59 (29.6)                    | .020*   |
| Postoperative pneumonia        | 3 (1.8)                         | 19 (9.6)                     | .002*   |
| Postoperative hospital stay    | 8 (2-113)                       | 9 (4-89)                     | .029*   |

Values are presented as median (min-max) or n (%). VATS, Video-assisted thoracoscopic surgery. *P < .05.

95% CI, 0.001-0.007; P = .008), surgical approach (β coefficient, –11.173; 95% CI, –17.263 to –5.082; P < .001), and albumin level (β coefficient, 0.847; 95% CI, 0.740-0.967; P = .014).

Finally, Table 5 shows the factors contributing to a decrease in the development of the postoperative complication C-D classification II or greater. There was significant association with oral management (OR, 0.503; 95% CI, 0.298-0.835; P = .009), exsmoker (quitting smoking 30 days or more before surgery) (OR, 2.153; 95% CI, 1.192-4.057; P = .014), and blood loss (OR, 1.003; 95% CI, 1.001-1.005; P = .025). The exsmoker group had a propensity to postoperative complications. In contrast, the oral management intervention group had the propensity to reduced postoperative complications.

**DISCUSSION**

This study aimed to investigate whether or not oral management intervention contributes to decreased postoperative complications in cases of pulmonary resection. Oral management before the operation seems to have a positive effect on the development of postoperative complications. Anatomically, the location of the trachea, the lungs, and the oral cavity may have a cause-and-effect relationship with these postoperative complications. The oral cavity and the trachea are connected by tracheal intubation. In particular, patients who underwent pulmonary resection have difficulty in coughing up sputum, a decline in respiratory function, an increase in sputum, and wound pain after surgery. These situations may have promoted postoperative complications. Therefore, oral management could be an important factor in decreasing postoperative complications for patients undergoing pulmonary surgery.

This study shows that, in cases of pulmonary resection, there has been a decline in the development of postoperative complications within a 4-year period. Although the advance of minimally invasive operations, such as video-assisted thoracic surgery, has had a positive effect on the prevention of postoperative complications, this study reveals that a decrease in postoperative hospital stay is not strongly linked to the operation method. Tables 3 and 5 show that there is no relationship between the operation method and postoperative pneumonia or C-D classification. However, this study also reveals that in cases of pulmonary resection, our extremely innovative oral management procedure leads to a decrease in the development of postoperative pneumonia, C-D classification II or greater, and postoperative hospital stay when compared with the nonintervention group.

ECOG PS 0 means a patient can work at a normal level of performance. PS 1 means the patient can perform tasks involved in ordinary living, but can not complete strenuous, aggressive work. Therefore a patient with PS 0 is better off than a patient with PS 1. However, making the distinction between PS 0 or PS 1 is difficult because it is a subjective evaluation. Because our data had a statistically significant result during the postoperative hospital stay period, PS was detected as a relevant confounding factor. In contrast, PS was not recognized as a relevant confounding factor in postoperative pneumonia and postoperative complications. Thus, this factor may have a relationship with recovery from general anesthesia damage (Table 4), but it might
TABLE 3. Association with postoperative pneumonia (n = 363)

| Variable* | Univariate | | | | Multivariate | | |
|---|---|---|---|---|---|---|---|
| | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
| Oral management | | | | |
| No | 1 | - | 1 | - |
| Yes | 0.177 (0.041-0.530) | 0.006 | 0.184 (0.042-0.571) | .009 |
| Gender | | | | |
| Male | 1 | - | - | - |
| Female | 0.535 (0.172-1.390) | .230 | - | - |
| Age (y) | 1.050 (0.998-1.110) | .074 | - | - |
| Body mass index | 1.033 (0.918-1.155) | .583 | - | - |
| ECOG performance status | | | | |
| 0 | 1 | - | - | - |
| 1 | 4.838 (1.734-12.459) | .001 | 2.883 (0.927-8.127) | .053 |
| %VC | 0.996 (0.972-1.004) | .738 | - | - |
| %FEV1 | 0.971 (0.935-1.002) | .130 | - | - |
| Comorbidities | | | | |
| Artificial dialysis† | 0.000 (0-∞) | .990 | - | - |
| Interstitial pneumonia† | 0.000 (0-∞) | .990 | - | - |
| Ischemic cardiac disease | 2.267 (0.342-8.849) | .300 | - | - |
| Cranial nerve disease or cerebrovascular disorder | 1.157 (0.062-6.221) | .891 | - | - |
| Diabetes mellitus | 1.984 (0.625-5.345) | .202 | - | - |
| Autoimmune disorder | 2.267 (0.342-8.849) | .300 | - | - |
| Arrhythmia (medical treatment) | 1.486 (0.079-8.239) | .711 | - | - |
| Hypertension | 0.530 (0.083-1.896) | .402 | - | - |
| Smoking status | | | | |
| Never smoked | 1 (ref) | - | - | - |
| Quit ≥30 d before surgery/exsmoker | 2.030 (0.723-7.222) | .216 | - | - |
| Quit <30 d before surgery/still smoking | 1.471 (0.198-7.881) | .664 | - | - |
| Preoperative therapy† | | | | |
| No | 1 (ref) | - | - | - |
| Yes | 0.000 (-∞) | .990 | - | - |
| Size of tumor (cm) | 1.148 (0.868-1.466) | .297 | - | - |
| Surgical side | | | | |
| Right | 1 | - | - | - |
| Left | 0.586 (0.189-1.523) | .305 | - | - |
| Operation time (min) | 1.002 (0.996-1.007) | .577 | - | - |
| Blood loss (mL) | 1.000 (0.998-1.001) | .799 | - | - |
| Surgical approach† | | | | |
| Thoracotomy | 1 | - | - | - |
| VATS | 2.845E+6 (0-) | .990 | - | - |
| Histologic type | | | | |
| Adenocarcinoma† | 1 | - | - | - |
| Nonadenocarcinoma | 2.589 (1.075-6.242) | .032 | 2.221 (0.852-5.708) | .096 |
| Pathologic staging† | | | | |
| 0† | 1 | - | - | - |
| IA and IB | 1.610E+6 (0-) | .991 | - | - |
| IIA and IIB | 5.245E+6 (0-) | .990 | - | - |
| IIIA and IIIB | 3.545E+6 (0-) | .990 | - | - |
| IV | 3.273E+6 (0-) | .990 | - | - |
| Albumin (g/dL) | 0.397 (0.175-0.951) | .030 | 0.562 (0.231-1.404) | .208 |

ECOG, Eastern Cooperative Oncology Group; %VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity; VATS, video-assisted thoracoscopic surgery. *Number of events = 22. Reference category. †P < .05. ‡An extremely large or near-zero odds ratio is due to the small number of postoperative pneumonia events (known as the complete separation).
| Variable                                      | Univariate                               | Multivariate                            |
|-----------------------------------------------|------------------------------------------|-----------------------------------------|
|                                               | Relative risk (95% CI) | P value | Relative risk (95% CI) | P value |
| Oral management                               |                                   |                                    |
| No*                                          | 1                                   | .        | 1                        | .        |
| Yes                                          | 0.810 (0.712-0.920)                  | .001    | 0.725 (0.645-0.815)      | <.001   |
| Gender                                        |                                   |                                    |
| Male*                                         | 1                                   | –       | 1                        | –       |
| Female                                        | 0.810 (0.708-0.928)                  | .002    | 1.063 (0.921-1.228)      | .401    |
| Age (y)                                       | 1.004 (0.997-1.011)                  | .257    |                          |         |
| Body mass index                               | 0.996 (0.979-1.014)                  | .644    |                          |         |
| ECOG performance status                       |                                   |                                    |
| 0*                                           | 1                                   | –       | 1                        | –       |
| 1                                            | 1.416 (1.159-1.743)                  | .001    | 1.246 (1.033-1.507)      | .022    |
| %VC                                          | 0.999 (0.998-1.0002)                 | .148    |                          |         |
| %FEV1                                        | 0.999 (0.998-1.001)                  | .288    |                          |         |
| Comorbidities                                 |                                   |                                    |
| Artificial dialysis                           | 1.097 (0.493-2.831)                  | .833    |                          |         |
| Interstitial pneumonia                        | 0.961 (0.566-1.725)                  | .888    |                          |         |
| Ischemic cardiac disease                      | 1.070 (0.797-1.460)                  | .659    |                          |         |
| Cranial nerve disease or cerebrovascular disorder | 1.334 (0.984-1.844)                  | .071    |                          |         |
| Diabetes mellitus                             | 1.193 (0.997-1.434)                  | .057    |                          |         |
| Autoimmune disorder                           | 1.211 (0.630-2.575)                  | .589    |                          |         |
| Arthrythmia (medical treatment)               | 1.225 (0.871-1.765)                  | .258    |                          |         |
| Hypertension                                  | 1.001 (0.842-1.195)                  | .993    |                          |         |
| Smoking status                                |                                   |                                    |
| Never smoked*                                 | 1                                   | –       | 1                        | –       |
| Quit ≥30 d before surgery/exsmoker            | 1.486 (1.288-1.714)                  | .001    | 1.241 (1.059-1.454)      | .007    |
| Quit <30 d before surgery/still smoking       | 1.373 (1.096-1.729)                  | .006    | 1.094 (0.867-1.378)      | .436    |
| Preoperative therapy                          |                                   |                                    |
| No*                                          | 1                                   | –       | 1                        | –       |
| Yes                                          | 0.737 (0.425-1.343)                  | .295    |                          |         |
| Size of tumor (cm)                            | 1.123 (1.078-1.171)                  | <.001   | 1.053 (1.010-1.099)      | .013    |
| Surgical side                                 |                                   |                                    |
| Right*                                        | 1                                   | –       | 1                        | –       |
| Left                                          | 0.880 (0.768, 1.010)                 | .069    |                          |         |
| Operation time (min)                          | 1.0026 (1.0018-1.0033)                | <.001   | 1.002 (1.001-1.003)      | <.001   |
| Blood loss (mL)                                | 1.0007 (1.0004-0.0010)                | <.001   | 1.0002 (1.0001-1.0004)   | .009    |
| Surgical approach                             |                                   |                                    |
| Thoracotomy*                                  | 1                                   | –       | 1                        | –       |
| VATS                                          | 0.456 (0.324-0.625)                  | <.001   | 0.700 (0.502-0.958)      | .025    |
| Histologic type                               |                                   |                                    |
| Adenocarcinoma*                               | 1                                   | –       | 1                        | –       |
| Nonadenocarcinoma                             | 1.313 (1.145-1.508)                  | <.001   | 1.037 (0.909-1.183)      | .589    |
| Pathologic staging                            |                                   |                                    |
| 0*                                           | 1                                   | –       | 1                        | –       |
| IA and IB                                     | 1.135 (0.758-1.667)                  | .529    | 0.953 (0.667-1.351)      | .789    |
| IIA and IIB                                   | 1.573 (1.040-2.337)                  | .028    | 1.158 (0.797-1.669)      | .434    |
| IIIA and IIIB                                 | 1.827 (1.203-2.728)                  | .004    | 1.125 (0.765-1.642)      | .542    |
| IV                                            | 1.080 (0.652-1.777)                  | .764    | 0.812 (0.740-0.967)      | .377    |
| Albumin (g/dL)                                | 0.675 (0.589-0.775)                  | <.001   | 0.847 (0.740-0.967)      | .014    |

ECOG, Eastern Cooperative Oncology Group; VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity; VATS, video-assisted thoracoscopic surgery. *Reference category. |P < .05.
**TABLE 5. Association of postoperative complications with Clavian-Dindo classification (n = 363)**

| Variable                        | Univariate                           | Multivariate                          |
|---------------------------------|---------------------------------------|----------------------------------------|
|                                 | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
| Oral management                 |                         |         |                         |         |
| No                              | 1                       | .019    | 1                       | .009    |
| Yes                             | 0.553 (0.334-0.902)     |         | 0.503 (0.298-0.835)    |         |
| Gender                          |                         |         |                         |         |
| Male                            | 1                       | .280    |                         |         |
| Female                          | 0.753 (0.445-1.249)     |         |                         |         |
| Age (y)                         | 1.024 (0.998-1.053)     | .080    |                         |         |
| Body mass index                 | 0.959 (0.894-1.025)     | .224    |                         |         |
| ECOG performance status         |                         |         |                         |         |
| 0                               | 1                       | .128    |                         | .788    |
| 1                               | 1.752 (0.830-3.556)     |         |                         |         |
| %VC                             | 0.999 (0.991-1.003)     |         |                         |         |
| %FEV1                           | 1.001 (0.995-1.005)     | .766    |                         |         |
| Comorbidities                   |                         |         |                         |         |
| Artificial dialysis             | 3.103 (0.122-79.033)    | .425    |                         |         |
| Interstitial pneumonia          | 0.767 (0.039-5.272)     | .814    |                         |         |
| Ischemic cardiac disease        | 1.300 (0.404-3.618)     | .631    |                         |         |
| Cranial nerve disease or cerebrovascular disorder | 1.126 (0.306-3.389) | .843 | | |
| Diabetes mellitus               | 1.498 (0.768-2.825)     | .221    |                         |         |
| Autoimmune disorder             | 6.279 (0.595-136.093)   | .136    |                         |         |
| Arrhythmia (medical treatment)  | 1.027 (0.224-3.534)     | .968    |                         |         |
| Hypertension                    | 1.343 (0.704-2.475)     | .355    |                         |         |
| Smoking status                  |                         |         |                         |         |
| Never smoked†                   | 1                       | .982    |                         |         |
| Quit ≥30 d before surgery/exsmoker | 2.235 (1.258-4.150) | .008‡   | 2.153 (1.192-4.057)    | .014‡   |
| Quit <30 d before surgery/still smoking | 1.460 (0.547-3.655) | .429 | | 1.370 (0.497-3.537)    | .526    |
| Preoperative therapy            |                         |         |                         |         |
| No                              | 1                       | .982    |                         |         |
| Yes                             | 0.843 (0.498-1.401)     | .517    |                         |         |
| Size of tumor (cm)              | 1.070 (0.911, 1.249)    | .398    |                         |         |
| Surgical side                   |                         |         |                         |         |
| Right                           | 1                       | .134    |                         |         |
| Left                            | 0.843 (0.498-1.401)     | .517    |                         |         |
| Operation time (min)            | 1.002 (0.999-1.005)     | .011†   | 1.003 (1.001-1.005)    | .025‡   |
| Blood loss (mL)                 | 1.003 (1.001-1.005)     | .011†   | 1.003 (1.001, 1.005)   | .025‡   |
| Surgical approach               |                         |         |                         |         |
| Thoracotomy†                    | 1                       | .512    |                         |         |
| VATS                            | 1.673 (0.431-11.020)    |         |                         |         |
| Histologic type                 |                         |         |                         |         |
| Adenocarcinoma†                 | 1                       | .468    |                         |         |
| Nonadenocarcinoma               | 1.210 (0.717-2.013)     |         |                         |         |
| Pathologic staging              |                         |         |                         |         |
| 0                               | 1                       | .950    |                         |         |
| IA and IB                       | 1.053 (0.252-7.156)     |         |                         |         |
| IIA and IIB                     | 2.189 (0.507-15.144)    | .342    |                         |         |
| IIIA and IIIB                   | 1.532 (0.343-10.796)    | .611    |                         |         |
| IV                              | 0.308 (0.013-3.722)     | .366    |                         |         |
| Albumin (g/dL)                  | 0.630 (0.370-1.076)     | .087    |                         |         |

ECOG, Eastern Cooperative Oncology Group; %VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity; VATS, video-assisted thoracoscopic surgery. *Number of events = 90. †Reference category. ‡P < .05.
not be an important related factor for postoperative complications (Tables 3 and 5).

Yoneyama and colleagues demonstrated that there was no difference in pneumonia mortality rate between dentulous and edentulous elderly patients who had undertaken oral care. This indicated that aspiration pneumonia developed regardless of whether periodontally compromised teeth were present or not. Therefore, we believe perioperative oral management should be separated from periodontal treatment. Our oral management procedure is different from traditional oral care in its ability to reduce postoperative complications. The term traditional oral care usually refers to oral hygiene instruction, measurement of periodontal pocket depth, removal of dental calculus (ie, scaling), professional mechanical tooth cleaning, and removal of tongue coating with a toothbrush. In contrast, we have not adopted the use of oral rinse, including oral antiseptic such as chlorhexidine, because a previous report indicated that irrigating the oropharynx with chlorhexidine gluconate in lung cancer surgery was not effective in decreasing postoperative complication. On the other hand, Bardia and colleagues showed that preoperative chlorhexidine use is associated with a reduction in postoperative pneumonia after cardiac surgery. Nonetheless, this study reported no significant difference in duration of mechanical ventilation, length of intensive care unit stay, and length of hospital stay between the group of patients where chlorhexidine was used and the group where it was not used. In addition, the generalizability to patients undergoing surgeries other than cardiac is still unclear. These reports suggest the role of preoperative chlorhexidine mouthwash in preventing postoperative complications remains unclear. Therefore, we have not adopted the use of chlorhexidine. Funahara and colleagues described that the microorganisms of the mouth were reduced through perioperative oral care with their number immediately growing again the day after surgery, and further, that the number of microorganisms on the tongue after surgery differed between patients with intraoral intake and patients undergoing fasting. We speculate that the outcome was caused by the uncontrollability of the autonomic nervous system in connection with operative and general anesthesia stress. We believe that the microorganisms of the mouth increase with the decline of saliva secretion under conditions of sympathetic nerve advantage immediately after surgery. Further, we surmise that the cause of this outcome was the difference in levels of salivation between them for reasons including the lack of stimulus in fasted patients. In fact, Ryu and colleagues demonstrated that a decline in saliva secretion was associated with the growth of oral microorganisms, indicating a strong correlation between the amount of saliva and the number of salivary microorganisms. Therefore, because the postoperative oral condition is usually poor with a lack of saliva, it is so much more important and effective to promote saliva secretion with oral gum and mucosa stimulation with a toothbrush rather than removing tongue coating and/or using chlorhexidine mouthwash around the perioperative period. Previous reports indicate that gum chewing has been shown to direct vagal afferent stimulation of smooth muscle fibers and to stimulate secretion from salivary glands. These inputs can induce the inhibitory effects of sympathetic afferent pathways. Experience tells us that stimulation of oral mucosa and jaw muscles with a toothbrush induces vigorous salivary secretion, this phenomenon being under the regulatory control of the cerebral cortical masticatory area. Oral mucosa and jaw muscle stimulation with a toothbrush may have an effect similar to gum chewing. Thus, toothbrush stimulation may promote the secretion of saliva and stimulate the parasympathetic nervous system. We observed a trend toward fewer hospital stay days with our oral mucosa and jaw muscle stimulation, as a result of its innocuous nature, safe method, and low cost. We believe that the main objective of postoperative oral assessment should be to check whether or not patients can successfully intake orally and discharge adequate salivary flow. Therefore, our oral management procedure not only prevents bacterial infection but may also assist perioperative patients with recovery from general anesthesia. However, it is natural that an oral management protocol does not have the ability to cope with an unexpected situation. In this study, blood loss is valid. This oral stimulation scheme resulted in a statistically strong difference, but also huge ranges of blood loss with as much as >6000 mL in the oral management group. It is likely that the oral management protocol doesn’t truly affect blood loss but may reflect confounding surgical factors that were not anticipated.

An interesting report described that there is a close correlation between the salivary and bronchoalveolar microbial compositions of patients with a greater salivary amylase activity level in bronchoalveolar lavage fluid. Lower levels of airway bacterial microbiome from the oral cavity may influence lung cancer recurrence after resection. Therefore, we believed that it was important to decrease oral microbiomes with sufficient amounts of saliva secretion in patients after lung surgery.

Many new efforts to reduce postoperative complications have been launched in recent years. The review studies regarding the effect of Enhanced Recovery After Thoracic Surgery on specific postoperative pulmonary complications, cost, and patient-reported outcomes such as pain scores and patient satisfaction scores are also warranted. In addition, the use of a comprehensive swallowing evaluation to detect aspiration before initiation of oral feedings after esophagectomy significantly reduced the incidence of pneumonia. This routine swallowing evaluation, incorporated into the postoperative care protocol after esophagectomy, demonstrated that postoperative pneumonia strongly predicted mortality. Since April 2016, our routine oral assessment was
incorporated into a perioperative management system for all patients who undergo surgery requiring general anesthesia. It is very important to create and introduce systems that prevent patients’ postoperative complications before they occur.

This study has some limitations. It may indicate that preoperative oral intervention is connected to the occurrence of postoperative complications in general. However, because this was a retrospective study with a small size population in a single institution there is a possibility of unmeasured and unknown confounding factors.

No data were obtained from several confounders, including levels of smoking and oral condition. In particular, Table 3 shows that oral management was only 1 relative factor for postoperative pneumonia. But, if the number of participants increases, it is possible that other relative factors may arise, including PS and histologic type.

Table 5 shows the factors contributing to a decrease in the development of postoperative complication C-D classification II or greater. There was significantly more association with the exsmoker group, who quit smoking 30 days or more before surgery than with the group currently smoking. This means we could not verify actual smoking status from clinical records.

This study may not be generalizable to other countries because all of its participants were residents of Japan, a country with a universal public health insurance scheme providing all residents with medical care services. This system is quite different from health insurance in other countries. Further study is required, where a traditional oral care group is compared with our innovative oral management group using oral mucosa stimulation.

CONCLUSIONS

This study reveals that, in cases of pulmonary resection, our extremely innovative oral management procedure can reduce postoperative pneumonia and C-D classification II or above when compared with the nonintervention group. Furthermore, our oral intervention leads to a decrease in postoperative hospital stay compared with the nonintervention group. This report proposes an innovative, simple, and efficient oral management procedure for the reduction of postoperative complications.

Conflict of Interest Statement

The authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

The authors thank T. Satomi, DDS, PhD, Department of Oral Surgery, Nippon Dental University, and K. Moriyama, MD, PhD, Department of Anesthesiology, Kyorin University Hospital, for their suggestions on how a patient’s oral and general condition relate. The authors also thank David Gotterson, BCom, LLB, BEd, for English language editing and formatting suggestions.

References

1. Khani SF, Henderson WG, DePalma RS, Mosca C, Healey NA, Kumbhani DJ. Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242:326-43.
2. Kazama HS, Martin M, Yoon JK, Wren SM. Long-term results of a postoperative pneumonia prevention program for the inpatient surgical ward. JAMA Surg. 2014;149:914-8.
3. Wilson W, Taubert KA, Gewirz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation. 2007;116:1736-54.
4. Iwata E, Hasegawa T, Yamada SI, Kawashita Y, Yoshimatsu M, Mizutani T, et al. Effects of perioperative oral care on prevention of postoperative pneumonia after lung resection: multivariate retrospective study with propensity score matching analysis. Surgery. 2019;165:1003-7.
5. Akutsu Y, Matsubara H, Shuto K, Shiratori T, Uesato M, Miyazawa Y, et al. Preoperative dental brushing can reduce the risk of postoperative pneumonia in esophageal cancer patients. Surgery. 2010;147:497-502.
6. Bergan EH, Tura BR, Lamas CC. Impact of improvement in perioperative oral health on nosocomial pneumonia in a group of cardiac surgery patients: a single arm prospective intervention study. Intensive Care Med. 2014;40:23-31.
7. Villamizar NR, Darrabie MD, Burfeind WR, Petersen RP, Onaitis MW, Toloza E, et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. J Thorac Cardiovasc Surg. 2009;138:419-25.
8. Allen MS, Blackmon S, Nichols FC, Cassivi SD, Shen KR, Wigle DA. Comparison of two national databases for general thoracic surgery. Ann Thorac Surg. 2015;100:1155-61.
9. Ishimaru M, Matsui H, Ono S, Hagiwara Y, Morita K, Yasunaga H. Preoperative oral care and effect on postoperative complications after major cancer surgery. Br J Surg. 2018;105:1688-96.
10. Ahn J, Yang L, Pastor BJ, Ganly I, Morris L, Pei Z, et al. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. PLoS One. 2011;6:e22788.
11. Rosan B, Lamont RJ. Dental plaque formation. Microbes Infect. 2000;2:1599-607.
12. Forrier F, Duvivier B, Boutigny H, Delzallez MR, Chopin C. Colonization of dental plaque: a source of nosocomial infections in intensive care unit patients. Crit Care Med. 1998;26:301-8.
13. Scannapieco FA, Stewart EM, Mylotte JM. Colonization of dental plaque by respiratory pathogens in medical intensive care patients. Crit Care Med. 1992;20:740-5.
14. Marino PJ, Wise MP, Smith A, Marchesi JR, Riggio MP, Lewis MAO, et al. Community analysis of dental plaque and endotracheal tube biofilms from mechanically ventilated patients. J Crit Care. 2017;39:149-55.
15. Oxnman DA, Issa NC, Marty FM, Patel A, Panizales CZ, Johnson NN, et al. Postoperative antibacterial prophylaxis for the prevention of infectious complications associated with tube thoracostomy in patients undergoing elective general thoracic surgery: a double-blind, placebo-controlled, randomized trial. JAMA Surg. 2013;148:440-6.
16. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications five-year experience. Ann Surg. 2009;250:187-96.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13.
18. Liu Q, Jiang H, Xu D, Jin J. Effect of gum chewing on ameliorating ileus following colorectal surgery: a meta-analysis of 18 randomized controlled trials. Int J Surg. 2017;47:107-15.
19. Yoneyama T, Yoshida M, Ohrui T, Mukaiyama H, Okamoto H, Hoshiba K, et al. Oral care reduces pneumonia in older patients in nursing homes. J Am Geriatr Soc. 2002;50:430-3.
20. Funahara M, Yanamoto S, Soutome S, Hayashida S, Umeda M. Clinical observation of tongue coating of perioperative patients: factors related to the number of bacteria on the tongue before and after surgery. *BMC Oral Health*. 2018;18:223.

21. D’Journo XB, Falcoz PE, Aliano M, Le Rochais JP, D’Annoville T, Massard G, et al. Oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate in lung cancer surgery: a randomized clinical trial. *Intensive Care Med*. 2018;44:578-87.

22. Bardia A, Blitz D, Dai F, Hersey D, Jinadasa S, Tickoo M, et al. Preoperative chlorhexidine mouthwash to reduce pneumonia after cardiac surgery: a systematic review and meta-analysis. *J Thorac Cardiovasc Surg*. 2019;158:1094-100.

23. Ryu M, Ueda T, Saito T, Yasui M, Ishihara K, Sakurai K. Oral environmental factors affecting number of microbes in saliva of complete denture wearers. *J Oral Rehabil*. 2017;37:194-201.

24. Rogers RC, McGinty DM, Hermann GE. Vagovagal reflex control of digestion: afferent modulation by neural and “endoneurocrine” factors. *Am J Physiol*. 1995;268:1-10.

25. Quah HM, Samad A, Neathey AJ, Hay DJ, Maw A. Does gum chewing reduce postoperative ileus following open colectomy for left-sided colon and rectal cancer? A prospective randomized controlled trial. *Colorectal Dis*. 2006;8:64-70.

26. Matros E, Rocha F, Zinner M, Wang J, Ashley S, Breen E, et al. Does gum chewing ameliorate postoperative ileus? Results of a prospective, randomized, placebo-controlled trial. *J Am Coll Surg*. 2006;202:773-8.

27. Travaglì RA, Rogers RC. Receptors and transmission in the brain-gut axis: potential for novel therapies. V. Fast and slow extrinsic modulation of dorsal vagal complex circuits. *Am J Physiol Gastrointest Liver Physiol*. 2001;281:595-601.

28. Maeda N, Kobashi M, Mitoh Y, Fujita M, Minagi S, Matsuo R. Differential involvement of two cortical masticatory areas in submandibular salivary secretion in rats. *Brain Res*. 2014;1543:200-8.

29. Patnaik SK, Cortes EG, Kannisto ED, Pannanitimon A, Dhillon SS, Liu S, et al. Lower airway bacterial microbiome may influence recurrence after resection of early-stage non–small cell lung cancer. *J Thorac Cardiovasc Surg*. 2021;161:419-29.

30. Khoury AL, McGinigle KL, Freeman NL, El-Zaatari H, Feltner C, Long JM. Enhanced recovery after thoracic surgery: systematic review and meta-analysis. *J Thorac Cardiovasc Surg Open*. 2021;7:370-91.

31. Berry MF, Atkins BJ, Tong BC, Harpole DH, D’Amico TA, Onaitis MW. A comprehensive evaluation for aspiration after esophagectomy reduces the incidence of postoperative pneumonia. *J Thorac Cardiovasc Surg*. 2010;140:1266-71.

**Key Words:** hospital stay period, lung cancer surgery, oral management, oral stimulation, postoperative complications